Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus

Michael Untch; Peter A. Fasching; Sara Y. Brucker; Wilfried Budach; Carsten Denkert; Renate Haidinger; Jens Huober; Christian Jackisch; Wolfgang Janni; Cornelia Kolberg-Liedtke; David Krug; Thorsten Kühn; Sibylle Loibl; Diana Lüftner; Volkmar Müller; Andreas Schneeweiss; Marc Thill; Nadia Harbeck; Christoph Thomssen

doi:10.1055/a-1483-2782

Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus

Michael Untch^*, Peter A. Fasching, Sara Y. Brucker, Wilfried Budach, Carsten Denkert, Renate Haidinger, Jens Huober, Christian Jackisch, Wolfgang Janni, Cornelia Kolberg-Liedtke, David Krug, Thorsten Kühn, Sibylle Loibl, Diana Lüftner, Volkmar Müller, Andreas Schneeweiss, Marc Thill, Nadia Harbeck, Christoph Thomssen

^*Corresponding author for this work

5 Citations (Scopus)

Abstract

This year's 17th St. Gallen (SG) Consensus Conference on the Treatment of Patients with Early Breast Cancer (SG-BCC) with the title Customizing local and systemic therapies for women with early breast cancer focused on the challenge of targeting the treatment of early breast cancer more specifically to the individual disease situation of each patient. As in previous years, a German working group of leading breast cancer experts discussed the results of the international SG-BCC 2021 in the context of the German guideline. It is helpful to compare the SG recommendations with the recently updated treatment recommendations of the Breast Commission of the German Working Group on Gynaecological Oncology (Arbeitsgemeinschaft Gynäkologische Onkologie e.V., AGO) and the S3 guideline because the SG-BCC panel comprised experts from different countries, which is why country-specific aspects can be incorporated into the SG recommendations. The German treatment recommendations of the AGO and the S3 guideline are based on current evidence. Nevertheless, any therapeutic decision must always undergo a risk-benefit analysis for the specific situation and to be discussed with the patient.

Translated title of the contribution	Behandlung von Patientinnen mit fruhem Mammakarzinom: Evidenz, Kontroversen, Konsens
Original language	English
Journal	Geburtshilfe und Frauenheilkunde
Volume	81
Issue number	6
Pages (from-to)	637-653
Number of pages	17
ISSN	0016-5751
DOIs	https://doi.org/10.1055/a-1483-2782
Publication status	Published - 01.06.2021

Research Areas and Centers

Research Area: Luebeck Integrated Oncology Network (LION)

DFG Research Classification Scheme

2.22-14 Hematology, Oncology
2.22-21 Gynaecology and Obstetrics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1055/a-1483-2782

Cite this

Untch, M., Fasching, P. A., Brucker, S. Y., Budach, W., Denkert, C., Haidinger, R., Huober, J., Jackisch, C., Janni, W., Kolberg-Liedtke, C., Krug, D., Kühn, T., Loibl, S., Lüftner, D., Müller, V., Schneeweiss, A., Thill, M., Harbeck, N., & Thomssen, C. (2021). Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus. Geburtshilfe und Frauenheilkunde, 81(6), 637-653. https://doi.org/10.1055/a-1483-2782

@article{134d3b57b86e49daa0519e838ab705bf,

title = "Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus",

abstract = "This year's 17th St. Gallen (SG) Consensus Conference on the Treatment of Patients with Early Breast Cancer (SG-BCC) with the title Customizing local and systemic therapies for women with early breast cancer focused on the challenge of targeting the treatment of early breast cancer more specifically to the individual disease situation of each patient. As in previous years, a German working group of leading breast cancer experts discussed the results of the international SG-BCC 2021 in the context of the German guideline. It is helpful to compare the SG recommendations with the recently updated treatment recommendations of the Breast Commission of the German Working Group on Gynaecological Oncology (Arbeitsgemeinschaft Gyn{\"a}kologische Onkologie e.V., AGO) and the S3 guideline because the SG-BCC panel comprised experts from different countries, which is why country-specific aspects can be incorporated into the SG recommendations. The German treatment recommendations of the AGO and the S3 guideline are based on current evidence. Nevertheless, any therapeutic decision must always undergo a risk-benefit analysis for the specific situation and to be discussed with the patient.",

author = "Michael Untch and Fasching, \{Peter A.\} and Brucker, \{Sara Y.\} and Wilfried Budach and Carsten Denkert and Renate Haidinger and Jens Huober and Christian Jackisch and Wolfgang Janni and Cornelia Kolberg-Liedtke and David Krug and Thorsten K{\"u}hn and Sibylle Loibl and Diana L{\"u}ftner and Volkmar M{\"u}ller and Andreas Schneeweiss and Marc Thill and Nadia Harbeck and Christoph Thomssen",

year = "2021",

month = jun,

day = "1",

doi = "10.1055/a-1483-2782",

language = "English",

volume = "81",

pages = "637--653",

journal = "Geburtshilfe und Frauenheilkunde",

issn = "0016-5751",

publisher = "Georg Thieme Verlag",

number = "6",

}

Untch, M, Fasching, PA, Brucker, SY, Budach, W, Denkert, C, Haidinger, R, Huober, J, Jackisch, C, Janni, W, Kolberg-Liedtke, C, Krug, D, Kühn, T, Loibl, S, Lüftner, D, Müller, V, Schneeweiss, A, Thill, M, Harbeck, N & Thomssen, C 2021, 'Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus', Geburtshilfe und Frauenheilkunde, vol. 81, no. 6, pp. 637-653. https://doi.org/10.1055/a-1483-2782

TY - JOUR

T1 - Treatment of Patients with Early Breast Cancer

T2 - Evidence, Controversies, Consensus

AU - Untch, Michael

AU - Fasching, Peter A.

AU - Brucker, Sara Y.

AU - Budach, Wilfried

AU - Denkert, Carsten

AU - Haidinger, Renate

AU - Huober, Jens

AU - Jackisch, Christian

AU - Janni, Wolfgang

AU - Kolberg-Liedtke, Cornelia

AU - Krug, David

AU - Kühn, Thorsten

AU - Loibl, Sibylle

AU - Lüftner, Diana

AU - Müller, Volkmar

AU - Schneeweiss, Andreas

AU - Thill, Marc

AU - Harbeck, Nadia

AU - Thomssen, Christoph

PY - 2021/6/1

Y1 - 2021/6/1

N2 - This year's 17th St. Gallen (SG) Consensus Conference on the Treatment of Patients with Early Breast Cancer (SG-BCC) with the title Customizing local and systemic therapies for women with early breast cancer focused on the challenge of targeting the treatment of early breast cancer more specifically to the individual disease situation of each patient. As in previous years, a German working group of leading breast cancer experts discussed the results of the international SG-BCC 2021 in the context of the German guideline. It is helpful to compare the SG recommendations with the recently updated treatment recommendations of the Breast Commission of the German Working Group on Gynaecological Oncology (Arbeitsgemeinschaft Gynäkologische Onkologie e.V., AGO) and the S3 guideline because the SG-BCC panel comprised experts from different countries, which is why country-specific aspects can be incorporated into the SG recommendations. The German treatment recommendations of the AGO and the S3 guideline are based on current evidence. Nevertheless, any therapeutic decision must always undergo a risk-benefit analysis for the specific situation and to be discussed with the patient.

AB - This year's 17th St. Gallen (SG) Consensus Conference on the Treatment of Patients with Early Breast Cancer (SG-BCC) with the title Customizing local and systemic therapies for women with early breast cancer focused on the challenge of targeting the treatment of early breast cancer more specifically to the individual disease situation of each patient. As in previous years, a German working group of leading breast cancer experts discussed the results of the international SG-BCC 2021 in the context of the German guideline. It is helpful to compare the SG recommendations with the recently updated treatment recommendations of the Breast Commission of the German Working Group on Gynaecological Oncology (Arbeitsgemeinschaft Gynäkologische Onkologie e.V., AGO) and the S3 guideline because the SG-BCC panel comprised experts from different countries, which is why country-specific aspects can be incorporated into the SG recommendations. The German treatment recommendations of the AGO and the S3 guideline are based on current evidence. Nevertheless, any therapeutic decision must always undergo a risk-benefit analysis for the specific situation and to be discussed with the patient.

UR - https://www.scopus.com/pages/publications/85108622668

U2 - 10.1055/a-1483-2782

DO - 10.1055/a-1483-2782

M3 - Scientific review articles

AN - SCOPUS:85108622668

SN - 0016-5751

VL - 81

SP - 637

EP - 653

JO - Geburtshilfe und Frauenheilkunde

JF - Geburtshilfe und Frauenheilkunde

IS - 6

ER -

Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus

Abstract

Research Areas and Centers

DFG Research Classification Scheme

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this